The Potential for Misuse and Abuse of Medications in ADHD: A Review (Q22241206)

PubMed

PubMed publication ID

25295651

8 February 2023

Daniel J. Walker

series ordinal

2

author given names

Daniel J

author last names

Walker

1 reference

PubMed

PubMed publication ID

25295651

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

8 February 2023

language of work or name

English

0 references

publication date

September 2014

0 references

published in

Postgraduate Medicine

0 references

volume

126

0 references

issue

5

0 references

page(s)

64-81

0 references

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Predictors of persistent ADHD: an 11-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Measurement of stigmatization towards adults with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

The relationship of malingering test failure to self-reported symptoms and neuropsychological findings in adults referred for ADHD evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

"Why is this so hard?" A review of detection of malingered ADHD in college students

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Symptom exaggeration by college adults in attention-deficit hyperactivity disorder and learning disorder assessments

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Catecholamine influences on dorsolateral prefrontal cortical networks

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Neuroimaging and drug taking in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

The effects of selective orbitofrontal cortex lesions on the acquisition and performance of cue-controlled cocaine seeking in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Differential control over cocaine-seeking behavior by nucleus accumbens core and shell

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Modulation of heroin and cocaine self-administration by dopamine D1- and D2-like receptor agonists in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Selective norepinephrine reuptake inhibition by atomoxetine prevents cue-induced heroin and cocaine seeking

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Methylphenidate and Atomoxetine Enhance Prefrontal Function Through α2-Adrenergic and Dopamine D1 Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Stimulation of postsynapse adrenergic α2A receptor improves attention/cognition performance in an animal model of attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Abuse liability assessment of atomoxetine in a drug-abusing population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Stimulant Formulation and Motivation for Nonmedical Use of Prescription Attention‐Deficit/Hyperactivity Disorder Medications in a College‐Aged Population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

The use, misuse and diversion of prescription stimulants among middle and high school students.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Attention-deficit/hyperactivity disorder: a selective overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Relationship between subjective effects of cocaine and dopamine transporter occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Amphetamine induces dopamine efflux through a dopamine transporter channel.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Effect of age on methylphenidate-induced conditioned taste avoidance and related BDNF/TrkB signaling in the insular cortex of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Altered responsiveness to cocaine in rats exposed to methylphenidate during development

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Enduring behavioral effects of early exposure to methylphenidate in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Pretreatment with methylphenidate sensitizes rats to the reinforcing effects of cocaine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Motivational systems in adolescence: possible implications for age differences in substance abuse and other risk-taking behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Characteristics and motives of college students who engage in nonmedical use of methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Characteristics of methylphenidate misuse in a university student sample

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Correlates of co-occurring ADHD in drug-dependent subjects: prevalence and features of substance dependence and psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Substance-use disorders in adolescents and adults with ADHD: focus on treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Potential adverse effects of amphetamine treatment on brain and behavior: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Effects of α-2A adrenergic receptor agonist on time and risk preference in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Cognitive enhancement as a treatment for drug addictions

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Clonidine abuse among opiate addicts

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Clonidine abuse in a methadone-maintained, clonazepam-abusing patient

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Differential central NOS-NO signaling underlies clonidine exacerbation of ethanol-evoked behavioral impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Abuse liability of centrally acting non-opioid analgesics and muscle relaxants--a brief update based on a comparison of pharmacovigilance data and evidence from the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

High impulsivity predicts relapse to cocaine-seeking after punishment-induced abstinence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Stimulant rebound: how common is it and what does it mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Medical use, illicit use, and diversion of abusable prescription drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Medical use, illicit use and diversion of prescription stimulant medication

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Stimulant prescription cautions: addressing misuse, diversion and malingering

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Attention-deficit/hyperactivity disorder and substance abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

ADHD in adults: current treatment trends with consideration of abuse potential of medications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

The misuse and diversion of prescribed ADHD medications by college students

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Motives and perceived consequences of nonmedical ADHD medication use by college students: are students treating themselves for attention problems?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Stimulant medication use in children: a 12-year perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Using symptom validity tests to detect malingered ADHD in college students.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

The nonmedical use of prescription ADHD medications: results from a national Internet panel

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Identifying students faking ADHD: Preliminary findings and strategies for detection

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Detection of malingered attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Detection of feigned ADHD in college students

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Detection of response bias and noncredible performance in adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Effectiveness of symptom validity measures in identifying cognitive and behavioral symptom exaggeration in adult attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

The relationship of noncredible performance to continuous performance test scores in adults referred for attention-deficit/hyperactivity disorder evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Misuse of prescribed stimulant medication for ADHD and associated patterns of substance use: preliminary analysis among college students

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Poison centers' experience with methylphenidate abuse in pre-teens and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Safety of stimulant treatment in attention deficit hyperactivity disorder: part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Methamphetamine and cardiovascular pathology: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Hospitalizations with amphetamine abuse among pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Literature Review: Update on Amphetamine Neurotoxicity and Its Relevance to the Treatment of ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Attention-deficit/hyperactivity disorder and early-onset substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Brain dopamine transporter levels in treatment and drug naïve adults with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Evaluating dopamine reward pathway in ADHD: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Correlates of nonmedical use of stimulants and methamphetamine use in a national sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Adolescent atomoxetine treatment in a rodent model of ADHD: effects on cocaine self-administration and dopamine transporters in frontostriatal regions

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Medical and nonmedical use of prescription stimulants: results from a national multicohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Nonmedical use of prescription stimulants in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Adults with ADHD: use and misuse of stimulant medication as reported by patients and their primary care physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Attention Deficit Hyperactivity Disorder (ADHD) is Associated with Early Onset Substance Use Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Psychostimulant Treatment and Risk for Substance Abuse Among Young Adults with a History of Attention-Deficit/Hyperactivity Disorder: APopulation-Based, Birth Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Stimulant Medications and Attention Deficit–Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

Depressed Dopamine Activity in Caudate and Preliminary Evidence of Limbic Involvement in Adults With Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Illicit use of clonidine in opiate-abusing pregnant women

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Concomitant abuse of clonidine and heroin

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Do Formulation Differences Alter Abuse Liability of Methylphenidate?

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Four cases of clonidine abuse

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

High risk for attention deficit hyperactivity disorder among children of parents with childhood onset of the disorder: a pilot study

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

1 reference

7 January 2021

Ability of college students to simulate ADHD on objective measures of attention

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Dissociation in conditioned dopamine release in the nucleus accumbens core and shell in response to cocaine cues and during cocaine-seeking behavior in rats.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Managing ADHD in the presence of comorbid substance use disorder

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021

Clinical correlates of inpatient suicide

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.09.2801

7 January 2021